BRPI0409206B8 - composições compreendendo cepas de lactobacillus em combinação com tanino e uso das referidas cepas de lactobacillus - Google Patents

composições compreendendo cepas de lactobacillus em combinação com tanino e uso das referidas cepas de lactobacillus

Info

Publication number
BRPI0409206B8
BRPI0409206B8 BRPI0409206A BRPI0409206A BRPI0409206B8 BR PI0409206 B8 BRPI0409206 B8 BR PI0409206B8 BR PI0409206 A BRPI0409206 A BR PI0409206A BR PI0409206 A BRPI0409206 A BR PI0409206A BR PI0409206 B8 BRPI0409206 B8 BR PI0409206B8
Authority
BR
Brazil
Prior art keywords
lactobacillus strains
tannin
combination
compositions
strains
Prior art date
Application number
BRPI0409206A
Other languages
English (en)
Inventor
Jeppsson Bengt
Molin Göran
Ahrné Siv
Original Assignee
Probi Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probi Ab filed Critical Probi Ab
Priority to BR122018068574-3A priority Critical patent/BR122018068574B1/pt
Publication of BRPI0409206A publication Critical patent/BRPI0409206A/pt
Publication of BRPI0409206B1 publication Critical patent/BRPI0409206B1/pt
Publication of BRPI0409206B8 publication Critical patent/BRPI0409206B8/pt
Publication of BRPI0409206C1 publication Critical patent/BRPI0409206C1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/169—Plantarum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/25—Lactobacillus plantarum
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/0102—Tannase (3.1.1.20)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/853—Lactobacillus
    • Y10S435/857—Lactobacillus plantarum

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

"composições compreendendo cepas de lactobacillus plantarum em combinação com tanino e cepas de lactobacillus plantarum". a invenção refere-se a uma composição que compreende uma ou mais cepas produtoras de tanase de lactobacillus tendo a capacidade de se aderir à mucosa intestinal humana em combinação com tanino. cepas produtoras de tanase de lactobacillus plantarum são uma delas.
BRPI0409206A 2003-04-04 2004-04-02 composições compreendendo cepas de lactobacillus em combinação com tanino e uso das referidas cepas de lactobacillus BRPI0409206C1 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122018068574-3A BR122018068574B1 (pt) 2003-04-04 2004-04-02 Uso de uma cepa produtora de lactobacillus plantarum de tanase para a preparação de um medicamento para o tratamento profilático ou curativo de lesão por isquemia/reperfusão

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0300994A SE527555C2 (sv) 2003-04-04 2003-04-04 Anti-inflammatorisk komposition innehållande tannasproducerande Lactobacillusstammar
US46305803P 2003-04-16 2003-04-16
PCT/SE2004/000509 WO2004087893A1 (en) 2003-04-04 2004-04-02 Compositions comprising lactobacillus plantarum strains in combination with tannin and new lactobacillus plantarum strains

Publications (4)

Publication Number Publication Date
BRPI0409206A BRPI0409206A (pt) 2006-03-28
BRPI0409206B1 BRPI0409206B1 (pt) 2018-11-06
BRPI0409206B8 true BRPI0409206B8 (pt) 2019-01-22
BRPI0409206C1 BRPI0409206C1 (pt) 2021-05-25

Family

ID=20290933

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122018068574-3A BR122018068574B1 (pt) 2003-04-04 2004-04-02 Uso de uma cepa produtora de lactobacillus plantarum de tanase para a preparação de um medicamento para o tratamento profilático ou curativo de lesão por isquemia/reperfusão
BRPI0409206A BRPI0409206C1 (pt) 2003-04-04 2004-04-02 composições compreendendo cepas de lactobacillus em combinação com tanino e uso das referidas cepas de lactobacillus

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122018068574-3A BR122018068574B1 (pt) 2003-04-04 2004-04-02 Uso de uma cepa produtora de lactobacillus plantarum de tanase para a preparação de um medicamento para o tratamento profilático ou curativo de lesão por isquemia/reperfusão

Country Status (19)

Country Link
US (3) USRE44400E1 (pt)
EP (2) EP1613740B1 (pt)
JP (1) JP4731469B2 (pt)
KR (1) KR101122916B1 (pt)
CN (2) CN1798831B (pt)
AT (1) ATE546516T1 (pt)
AU (1) AU2004225568B2 (pt)
BR (2) BR122018068574B1 (pt)
CA (1) CA2521220C (pt)
DK (1) DK1613740T3 (pt)
ES (2) ES2751101T3 (pt)
HK (2) HK1094004A1 (pt)
PL (2) PL2163162T3 (pt)
PT (1) PT1613740E (pt)
RU (1) RU2356942C2 (pt)
SE (1) SE527555C2 (pt)
SI (1) SI1613740T1 (pt)
WO (1) WO2004087893A1 (pt)
ZA (1) ZA200507938B (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE528382C2 (sv) * 2004-10-05 2006-10-31 Probi Ab Probiotiska lactobacillusstammar för förbättrad vaginal hälsa
SE529199C2 (sv) * 2005-07-05 2007-05-29 Probi Ab Förstärkt absorption
WO2007009187A1 (en) * 2005-07-22 2007-01-25 Tarac Technologies Pty Ltd Polyphenol and probiotic containing nutritional supplement
DK3067057T3 (da) 2005-09-28 2023-02-13 Nordic Rebalance As Probiotisk fermenteret cerealiesammensætninger til anvendelse ved behandling af gastrointestinale lidelser forårsaget af pro-inflammatoriske bakterier
SI1951272T1 (sl) 2005-10-06 2016-10-28 Probi Ab Uporaba lactobacillus za zdravljenje virusnih infekcij
US20080269142A1 (en) * 2006-10-23 2008-10-30 Ian Blair Endogenous thiadiazabicyclo glutathione-adduct
WO2008075949A1 (en) * 2006-12-20 2008-06-26 Friesland Brands B.V. Modulation of human microsomal triglyceride transfer protein (mtp or mttp) gene expression by food-grade/ingested dietary microorganisms
BRPI0808522A8 (pt) * 2007-03-01 2017-10-10 Probi Ab Uso de lactobacillus plantarum para aumentar diversidade bacterial
SE532899C2 (sv) * 2007-06-08 2010-05-04 Probi Ab Förfarande genom fermentering med Lactobacillus plantarum för tillhandahållande av en insulinsvarsreducerande produkt och dess användning farmaceutiskt eller i livsmedel
KR20110004407A (ko) * 2008-04-30 2011-01-13 네스텍 소시에테아노님 가수분해된 클로로겐산을 포함하는 커피 음료 제조용 조성물
US20110046235A1 (en) * 2008-04-30 2011-02-24 Nestec S.A. Products comprising, and uses of, decarboxylated phenolic acids derived from chlorogenic acids of coffee
EE05341B1 (et) * 2008-05-13 2010-08-16 O� Tervisliku Piima Biotehnoloogiate Arenduskeskus Isoleeritud mikroorganismi tvi Lactobacillus plantarum Inducia DSM 21379 kui organismi loomulikku kaitsev?imet t?stev probiootik, seda sisaldav toiduaine ja kompositsioon ning mikroorganismi kasutamine rakulist immuunsust t?stva ravimi valmistamisek
EP2210505A1 (en) * 2009-01-27 2010-07-28 Nestec S.A. Composition comprising caftaric acid and/or derivatives thereof
EP2210504A1 (en) * 2009-01-27 2010-07-28 Nestec S.A. Composition comprising chicoric acid and/or derivatives thereof
EP2485744A4 (en) * 2009-10-09 2014-01-22 Prothera Inc COMPOSITIONS AND METHODS COMPRISING THE PEDIOCOCCUS TO REDUCE AT LEAST ONE SYMPTOM ASSOCIATED WITH DEVELOPMENT-INVASIVE DISORDER IN A PERSON IN WHICH A DEVELOPMENT-INVASIVE DISORDER HAS BEEN DIAGNOSED
RU2580040C2 (ru) 2009-12-22 2016-04-10 Проби Аб Неферментированные композиции, включающие фракцию на основе злаков и пробиотик, и их применение
TWI401086B (zh) * 2010-07-20 2013-07-11 Univ China Medical 胚芽乳酸桿菌及其用途
ITMI20110793A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri probiotici e composizione sinbiotica contenente gli stessi destinata alla alimentazione dei neonati.
CN113151045A (zh) 2011-06-10 2021-07-23 株式会社爱茉莉太平洋 分离自茶树叶的新型植物乳杆菌
CN103173379A (zh) * 2011-12-22 2013-06-26 熊津食品有限公司 新型的红参发酵用微生物，及其利用该微生物的红参发酵液和红参发酵饮料
TWI463986B (zh) 2012-08-29 2014-12-11 Univ China Medical 胚芽乳酸桿菌ｃｍｕ９９５菌株之新用途
US11173170B2 (en) 2014-11-05 2021-11-16 Optibiotix Limited Prebiotic composition and its methods of production
US10226492B2 (en) 2014-11-25 2019-03-12 Dsm Ip Assets B.V. Probiotic and new biomarker
RU2600445C1 (ru) * 2015-09-21 2016-10-20 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московская государственная академия ветеринарной медицины и биотехнологии - МВА имени К.И. Скрябина" (ФГБОУ ВО МГАВМиБ - МВА имени К.И. Скрябина) Способ биоиндикации состояния двухстворчатых моллюсков в условиях техногенного загрязнения среды обитания
GB201600975D0 (en) 2016-01-19 2016-03-02 Probi Ab Novel strain of probiotic bacteria and compositions and uses thereof
IT201700057079A1 (it) * 2017-05-25 2018-11-25 Probiotical Spa Batterioterapia a base di composizioni batteriche per il trattamento di malattie neurodegenerative
WO2019242839A1 (en) * 2018-06-18 2019-12-26 Probi Ab Lactobacillus plantarum compositions and uses thereof
KR20210114929A (ko) * 2018-11-05 2021-09-24 마블바이옴 인코포레이티드 엘라기탄닌을 포함하는 미생물 조성물 및 사용 방법
US20220175893A1 (en) * 2019-03-05 2022-06-09 The Texas A&M University System Combinations of tannase and probiotic formulations and methods of use for improving tannin metabolism
GB201908154D0 (en) * 2019-06-07 2019-07-24 Probi Ab Lactobacillus compositions and uses thereof
CN111500655B (zh) * 2020-03-19 2021-03-05 北京北农科技有限公司 一种五倍子单宁制备新工艺
CN112386614B (zh) * 2020-11-25 2022-11-08 天津科技大学 植物乳杆菌ma2在制备预防或改善阿尔茨海默症药物或食品方面中的应用
KR102390694B1 (ko) * 2021-07-13 2022-04-29 한국식품연구원 락티플란티바실러스 파라플란타룸 WiKim0130을 포함하는 암의 예방, 개선 또는 치료용 조성물
CN114107161B (zh) * 2021-11-15 2023-06-20 泸州老窖股份有限公司 一种混合驯化菌株降解石榴皮生产鞣花酸的方法
CN113980858B (zh) * 2021-11-18 2023-05-02 上海植酵盛生物科技有限公司 一株产高活性单宁酶的植物乳杆菌yl399及其在制备党参发酵饲料中的应用
CN117384879B (zh) * 2023-01-13 2024-04-30 中国农业科学院茶叶研究所 一种适应茶汁体系的耐酸单宁酶制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2453763A1 (fr) 1979-04-14 1980-11-07 Teves Gmbh Alfred Regulateur de force de freinage a deux circuits, comportant un piston d'arret actionnable hydrauliquement
JPS5785326A (en) 1980-11-14 1982-05-28 Asahi Glass Co Ltd Stabilization of flon
JPS6425726A (en) 1987-04-24 1989-01-27 Yuutoku Yakuhin Kogyo Kk Agent for eliminating active oxygen free radical
SE463796B (sv) * 1988-03-09 1991-01-28 Carl Erik Albertsson Foerfarande foer framstaellning av en naeringskomposition och daervid framstaelld naeringskomposition
SE469875C (sv) 1991-07-25 1997-04-14 Probi Ab Stam av tarmkoloniserande Lactobacillus samt komposition för profylax eller behandling av infektioner i magtarmkanalen
JP3459837B2 (ja) 1992-05-12 2003-10-27 太陽化学株式会社 生菌粉末
JP4127863B2 (ja) 1993-03-04 2008-07-30 太陽化学株式会社 腸内環境改善組成物
SE9501056D0 (sv) * 1995-03-23 1995-03-23 Probi Ab Epithelial adherent lactobacilli
SE9501719D0 (sv) * 1995-05-09 1995-05-09 Probi Ab Pharmaceutical composition
SE510753C2 (sv) * 1997-08-05 1999-06-21 Probi Ab Användning av en stam av Lactobacillus för tillverkning av ett läkemedel för reduktion av fibrinogenhalten i blod
CA2345110A1 (en) * 1998-10-01 2000-04-13 Probi Ab Reduction of oxidative stress factors
FR2789580A1 (fr) * 1999-02-12 2000-08-18 Oreal Compositions cosmetiques antisolaires a base d'un melange synergique de filtres et utilisations
SE523771C2 (sv) * 1999-05-21 2004-05-18 Probi Ab Sportdryck innehållande mikronäringsämnen i kombination med levande laktobaciller
SE0004124D0 (sv) 2000-11-10 2000-11-10 Probi Ab New use
KR100549193B1 (ko) * 2002-10-23 2006-02-02 (주)바이오뉴트리젠 인삼 및 폴리페놀계 물질 또는 바이오플라보노이드계 물질을 포함하는 식물의 분말 또는 추출물을 포함하는 항비만용 식품

Also Published As

Publication number Publication date
EP2163162A1 (en) 2010-03-17
HK1094004A1 (en) 2007-03-16
USRE46718E1 (en) 2018-02-20
JP4731469B2 (ja) 2011-07-27
RU2005134223A (ru) 2006-03-10
EP2163162B1 (en) 2019-08-07
WO2004087893A1 (en) 2004-10-14
RU2356942C2 (ru) 2009-05-27
EP1613740A1 (en) 2006-01-11
CN102210717B (zh) 2013-02-06
ATE546516T1 (de) 2012-03-15
CN102210717A (zh) 2011-10-12
AU2004225568A1 (en) 2004-10-14
BRPI0409206B1 (pt) 2018-11-06
ZA200507938B (en) 2007-03-28
CN1798831B (zh) 2011-05-18
PL2163162T3 (pl) 2020-02-28
CN1798831A (zh) 2006-07-05
USRE44400E1 (en) 2013-07-30
JP2006521817A (ja) 2006-09-28
ES2751101T3 (es) 2020-03-30
BRPI0409206A (pt) 2006-03-28
KR20060005356A (ko) 2006-01-17
CA2521220C (en) 2014-05-27
EP1613740B1 (en) 2012-02-22
CA2521220A1 (en) 2004-10-14
SE0300994D0 (sv) 2003-04-04
BRPI0409206C1 (pt) 2021-05-25
US7507572B2 (en) 2009-03-24
HK1162937A1 (en) 2012-09-07
WO2004087893A9 (en) 2006-03-30
BR122018068574B1 (pt) 2021-10-26
SE0300994L (sv) 2004-10-05
PT1613740E (pt) 2012-05-28
KR101122916B1 (ko) 2012-06-13
ES2382930T3 (es) 2012-06-14
DK1613740T3 (da) 2012-05-21
SE527555C2 (sv) 2006-04-11
SI1613740T1 (sl) 2012-09-28
PL1613740T3 (pl) 2012-07-31
AU2004225568B2 (en) 2008-02-14
US20060257384A1 (en) 2006-11-16

Similar Documents

Publication Publication Date Title
BRPI0409206B8 (pt) composições compreendendo cepas de lactobacillus em combinação com tanino e uso das referidas cepas de lactobacillus
ATE517125T1 (de) ANTIKÖRPER GEGEN ßDEATH RECEPTOR 4ß (DR4) UND DEREN VERWENDUNGEN
ATE478120T1 (de) Thermoplastische zusammensetzungen
BR0211442A (pt) Cepas de bifidobacterium probióticas
BR9709881A (pt) "formulação de borracha de nitrila mole"
BR0113608A (pt) Composição cosmética clara em emulsão antiperspirante e/ou desodorante
CY1110505T1 (el) Ανθρωπινα αντισωματα dr4 και χρησεις αυτων
BR9900972A (pt) Uso de uma associação de lactobacilos para a preparação de uma composição para tratamento de vaginoses e vaginites, e composições farmacêuticas assim preparadas.
ATE163042T1 (de) Lactobazillusstämme menschlichen ursprungs, ihre zusammensetzung und deren verwendung
BR0116032A (pt) imidazoquinolinas substituìdas com sulfonamido éster
BR0100046A (pt) Copolìmeros reticulados solúveis em água ou intumescìveis em água
BRPI0416292A (pt) composições estabilizadas compreendendo probióticos
BR9916132B1 (pt) composiÇÕes e utilizaÇço das mesmas.
DK1590047T4 (da) Sammensætning, som omfatter lactobacillus eller bifidobacterium, og anvendelse deraf
BR0317822A (pt) Composição fluoroquìmica
BR9914185A (pt) Confeitaria hidrocolóide
BR9914833A (pt) Composição aquosa de revestimento e uso da mesma
BR0013110A (pt) Forma oral de administração contendo microorganismos probióticos
CY1114133T1 (el) ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ γ-ΦΑΙΝΥΛ-Δ-ΛΑΚΤΑΜΕΣ ΚΑΙ ΧΡΗΣΕΙΣ ΠΟΥ ΣΧΕΤΙΖΟΝΤΑΙ ΠΡΟΣ ΑΥΤΕΣ
BR0008912A (pt) Cepas de bactérias do ácido láctico capazes de prevenir a diarréia
TR200400363T4 (tr) Antibiyotikten / Antibiyotiklerden oluşan bir preparatın imalatı ve kullanımı
EP2213302A3 (en) DR4 antibodies and uses thereof
DE69411110D1 (de) Spielbälle, drucklose Tennisbälle und Kautschukzusammensetzungen für ihre Herstellung
EP1555250A3 (de) Schlichtezusammensetzung
BR0101691B1 (pt) composições de pelìcula de poliolefina com propriedades de antiembaçamento permanentes e uso das referidas composições.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/35 (2006.01), A23L 33/135 (2016.01), A61K

B15K Others concerning applications: alteration of classification

Ipc: C12N 1/20 (2006.01), A61K 31/35 (2006.01), A61K 35

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/11/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/11/2018, OBSERVADAS AS CONDICOES LEGAIS. (CO) REFERENTE A RPI 2496 DE 06/11/2018,QUANTO AO QUADRO REIVINDICATORIO.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/04/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF